|
 Myriad's shares fell 12 percent in before the bell
on Tuesday.
The company had filed a complaint against Ambry in the U.S. District
Court of Utah last July, alleging that Ambry's tests infringed some
of its patents.
Myriad has been seeking a preliminary injunction to prevent Ambry
from selling the tests, pending final decision on the case.
Myriad said it believed its patents were valid, enforceable and
infringed, and was confident that it would prevail based on the full
evidence.
A trial date has not been scheduled, Myriad said in a regulatory
filing.
Myriad shares were down 12 percent at $33.21 in trading before the
bell.
(Reporting by Esha Dey in Bangalore;
editing by Saumyadeb Chakrabarty)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
